Literature DB >> 384187

Vincristine and prednisone vs vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children.

J Herson, K A Starling, P G Dyment, G B Humphrey, J Pullen, T Vats.   

Abstract

Second remission induction rates for vincristine and prednisone alone (VP) and vincristine, L-asparaginase, and prednisone (VLP) are compared for children with acute lymphocytic leukemia. No evidence of a significant difference between the second induction complete remission rate for VP (78.6%) and VLP (73.7%) was found. Duration of first remission and prognostic group at initial diagnosis (defined on the basis of age and white blood count at initial diagnosis) are shown to be significant prognostic factors for second remission induction; and three second remission induction risk groups are defined on the basis of these two factors. Periodic reinforcement with prednisone in first remission does not appear to lower second induction complete response (CR) rates for VP. There was no evidence of a significant difference in the frequency of occurrence of severe toxicity between the VP and VLP regimens.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 384187     DOI: 10.1002/mpo.2950060408

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  4 in total

1.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

2.  A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.

Authors:  T Vats; G Buchanan; P Mehta; A Ragab; E Hvizdale; R Nitschke; M Link; G P Beardsley; D Maybee; J Krischer
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

3.  Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse.

Authors:  G Garay; J Milone; E Dibar; S Pavlovsky; R Kvicala; F Sackmann Muriel; D Montres Varela; M Eppinger-Helft
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 4.  Childhood acute lymphoblastic leukaemia: a review.

Authors:  M L Willoughby
Journal:  J R Soc Med       Date:  1982-06       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.